Ciclosporin and refractory colitis

European Journal of Gastroenterology and Hepatology

Volumn 15, Issue 3, 2003, Pages 239-244

  Hawthorne, A Barney ^a  

^a LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Ciclosporin; Immunosuppressive agents; Ulcerative colitis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN; AZATHIOPRINE; CARBAMAZEPINE; CIMETIDINE; CLARITHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; DANAZOL; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; GESTAGEN; HYPERICUM PERFORATUM EXTRACT; ITRACONAZOLE; KETOCONAZOLE; MERCAPTOPURINE; METHYLPREDNISOLONE; MICONAZOLE; NICARDIPINE; PHENOBARBITAL; PHENYTOIN; QUINOLONE DERIVATIVE; RIFAMPICIN; TICLOPIDINE; TRIMETHOPRIM; URSODEOXYCHOLIC ACID; VERAPAMIL;

CLINICAL TRIAL; COLITIS; COLON RESECTION; DRUG FATALITY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; FOOD DRUG INTERACTION; GRAPEFRUIT; HUMAN; MICROEMULSION; NEPHROTOXICITY; NEUROTOXICITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY;

COLITIS, ULCERATIVE; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 0037340337     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200303000-00005     Document Type: Review

References (51)

1. Travis SPL, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP. Predicting outcome in severe ulcerative colitis. Gut 1996; 38:905-910.
2. Atkinson KA, McDonald JW, Lamba B, Feagan BG. Intravenous cyclosporine for severe attacks of ulcerative colitis: a survey of Canadian gastroenterologists. Can J Gastroenterol 1997; 11:583-587.
3. Stack WA, Williams D, Stevenson M, Logan RF. Immunosuppressive therapy for ulcerative colitis: results of a nation-wide survey among consultant physician members of the British Society of Gastroenterology. Ailment Pharmacol Ther 1999; 13:569-575.
4. Meuwissen SG, Ewe K, Gassull MA, Geboes K, Jewell D, Pallone F, et al. IOIBD questionnaire on the clinical use of azathioprine, 6-mercaptopurine, cyclosporin A and methotrexate in the treatment of inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2000; 12:13-18.
5. ++ signals and immunosuppression. Nature 1996; 383:837-840.
6. Wiederrecht G, Lam E, Hung S, Martin M, Sigal N. The mechanism of action of FK-506 and cyclosporin A. Ann NY Acad Sci 1993; 696:9-19.
7. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000; 47:119-125.
8. Kim WU, Cho ML, Kim SI, Yoo WH, Lee SS, Joo YS, et al. Divergent effect of cyclosporine on Th1/Th2 type cytokines in patients with severe, refractory rheumatoid arthritis. J Rheumatol 2000; 27:324-331.
9. Gupta S, Keshavarzian A, Hodgson HJF. Cyclosporin in ulcerative colitis. Lancet 1984; ii:1277-1278.
10. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330:1841-1845. Randomized controlled trial of intravenous ciclosporin infusion versus placebo in patients failing 7 days of intravenous steroids. Dramatic short-term benefit, with 82% response on ciclosporin, versus no response on placebo. This small trial established intravenous infusion of 4 mg/kg/day as the dose of choice.
11. Kornbluth A, Present DH, Lichtiger S, Hanauer S. Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol 1997; 92:1424-1428. Practical information about how to administer ciclosporin safely, and recommendations for screening and monitoring patients.
12. Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94:1587-1592.
13. Fernandez-Benares F, Bertran X, Esteve-Comas M, Cabre E, Menacho M, Humbert P, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996; 91:2498-2499.
14. Actis GC, Bresso F, Astegiano M, Demarchi B, Sapone N, Boscaglia C, et al. Safety and efficacy of azathioprine in the maintenance of cyclosporin-induced remission of ulcerative colitis. Aliment Pharmacol Ther 2001; 15:131-137.
15. Ramakrishna J, Langhans N, Calenda K, Grand RJ, Verhave M. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Ped Gastroenterol Nutr 1996; 22:296-302.
16. Haslam N, Hearing SD, Probert CSJ. Audit of cyclosporin use in inflammatory bowel disease: limited benefits, numerous side-effects. Eur J Gastroenterol Hepatol 2000; 12:657-660.
17. Cohen RD, Brodsky AL, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin. Inflamm Bowel Dis 1999; 5:1-10.
18. Rowe FA, Walker JH, Karp LC, Vasiliauskas EA, Plevy SE, Targan SR. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol 2000; 95:2000-2008.
19. Santos J, Baudet S, Casellas F, Guarner L, Vilaseca J, Malagelada J-R. Efficacy of intravenous cyclosporin for steroid refractory attacks of ulcerative colitis. J Clin Gastroenterol 1995; 20:285-289.
20. Stack WA, Long RG, Hawkey CJ. Short- and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther 1998; 12:973-978.
21. Carbonnel F, Boruchowicz A, Duclos B, Soule JC, Lerebours E, Leman M, et al. Intravenous cyclosporine in attacks of ulcerative colitis. Short-term and long-term responses. Dig Dis Sci 1996; 41:2471-2476.
22. Actis GC, Aimo G, Priolo G, Moscato D, Rizzetto M, Pagni R. Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid-refractory ulcerative colitis: an open-label retrospective trial. Inflamm Bowel Dis 1998; 4:276-279. Large series of patients receiving low-dose intravenous or oral ciclosporin.
23. Lanese DM, Conger JD. Effect of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest 1993; 91:2144-2149.
24. Ruggenenti P, Perico N, Mosconi L, Gaspari F, Benigni A, Amuchastegui CS, et al. Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993; 43:706-711.
25. Mihatsch MJ, Ryffel B, Gudat F, Thiel G. Cyclosporine nephropathy. In: Tisher CC, Brenner BM (editors). Renal Pathology: with Clinical and Functional Correlations. 2nd edition. Philadelphia: Lippincott; 1994, pp. 1641-1681.
26. Quan VA, Sauders BP, Hicks BH, Sladen GE. Cyclosporin treatment for ulcerative colitis complicated by fatal Pneumocystis carinii pneumonia. BMJ 1997; 314:363-364.
27. Stack WA, Richardson PD, Logan RPH, Mahida YR, Hawkey CJ. Nocardia asteroides lung abscess in acute ulcerative colitis treated with cyclosporine. Am J Gastroenterol 2001; 96:2255-2256.
28. Caroli A, Fregoese D, Di Falco G, D'Inca R. Aspergillus fumigatus pneumonia during cyclosporine treatment for ulcerative colitis. Am J Gastroenterol 2000; 95:3016-3017.
29. Vega R, Bertran X, Menacho M, Domenech E, Moreno de Vega V, Hombrados M, et al. Cytomegalovirus infection in patients with inflammatory bowel disease. Am J Gastroenterol 1999; 94:1053-1056.
30. Humphreys TR, Leyden JJ. Acute reversible central nervous system toxicity associated with low-dose oral cyclosporine therapy. J Am Acad Dermatol 1993; 29:490-492.
31. Durrant S, Chipping PM, Palmer S, Gordon-Smith EC. Cyclosporin A, methylprednisolone, and convulsions. Lancet 1982; ii:829-830.
32. Thompson CB, June CH, Sullivan KM, Thomas ED. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet 1984; ii:1116-1120.
33. De Green PC, Aksamit AJ, Rakela J, Gerbes GS, Krom RAF. Central nervous system toxicity after liver transplantation. N Engl J Med 1987; 317:861-866.
34. De Groen PC. Cyclosporine, low-density lipoprotein, and cholesterol. Mayo Clin Proc 1988; 63:1012-1021.
35. Hemming AAW, Greig PD, Cattral MS, Chung SW, Lilly LB, Aljumah AA, et al. A microemulsion of cyclosporine without intravenous cyclosporine in liver transplantation. Transplantation 1996; 62:1798-1802.
36. Actis GC, Volpes R, Rizzetto M. Oral microemulsion cyclosporin to reduce steroids rapidly in chronic active ulcerative colitis. Eur J Gastroenterol Hepatol 1999; 11:905-908.
37. Oppong K, Record CO. Neoral may be as effective as intravenous cyclosporine in the treatment of steroid-resistant ulcerative colitis. Am J Gastroenterol 1998; 93:1188-1189.
38. Van Assche G, D'Haens G, Noman M, Hiele M, Asnong K, Aerden I, et al. Randomized double blind comparison of 4 mg/kg versus 2 mg/kg IV cyclosporine in severe ulcerative colitis. Gastroenterology 2002; 122:A81.
39. D'Haens G, Lemmens L, Geboes K, Candeputte L, Van Acker F, Mortelmans L, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120:1323-1329. A randomized trial showing that monotherapy with i.v. ciclosporin is as effective as i.v. methylprednisolone. Forty per cent of non-responders to either therapy alone improved on combined treatment. There was no severe toxicity in the ciclosporin group, and treatment without corticosteroids may be safer, but combined therapy still seems more effective.
40. Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994; 106:1429-1435. Ciclosporin enemas are ineffective in distal colitis.
41. Fleshner PR, Michelassi F, Rubin M, Hanauer SB, Plevy SE, Targan SR. Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to ciclosporin. Dis Colon Rectum 1995; 38:1241-1245.
42. Pinna-Porter M, Arese P, Bona R, Falletto E, Schieroni R, Villata E, et al. Severe steroid-unresponsive ulcerative colitis. Outcomes of restorative proctocolectomy in patients undergoing cyclosporin treatment. Dis Colon Rectum 2000; 43:609-614.
43. Hyde GM, Jewell DP, Kettlewell MGW, Mortensen NJMcC. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001; 44:1436-1440.
44. Scott AM, Myers GA, Harms BA. Pneumocystis carinii pneumonia post-restorative proctocolectomy for ulcerative colitis: a role for perioperative prophylaxis in the cyclosporine era? Report of a case and review of the literature. Dis Colon Rectum 1997; 40:973-976.
45. Lichtiger S, Present DH. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990; 336:16-19.
46. Van Gossum A, Schmit A, Adler M, Chioccioli C, Fiasse R, Louwagie P, et al. Short- and long-term efficacy of cyclosporin administration in patients with acute severe ulcerative colitis. Acta Gastroenterol Belg 1997; 60:197-200.
47. Wenzl HH, Petritsch W, Aichbichler BW, Hinterleitner TA, Fleischmann G, Krejs GJ. Short-term efficacy and long-term outcome of cyclosporine treatment in patients with severe ulcerative colitis. Z Gastroenterol 1998; 36:287-293.
48. Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol 1998; 10:411-413. Survey of ciclosporin use in 50 patients with 56% short-term and 40% long-term response (mean 19 months).
49. Hermida-Rodriguez C, Cantero Perona J, Garcia-Valriberas R, Pajares Garcia JM, Mate-Jimenez J. High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease. Hepatogastroenterology 1999; 46:2265-2268.
50. Treem WR, Cohen J, Davis PM, Justinich CJ, Hyams JS. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum 1995; 38;474-479.
51. Navazo L, Salata H, Morales S, Dorta MC, Perez F, de las Casas D, Aviles J. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand J Gastroenterol 2001; 36:610-614.